Viome Life Sciences

Viome Life Sciences

Personalized nutrition via microbiome tests

Overview

Viome Life Sciences offers personalized nutrition and gut-health solutions by analyzing the microbiome and cellular health through health tests. Using mRNA technology and AI, it translates these results into individualized diet plans and supplement recommendations, including probiotics. Revenue comes from selling health tests, personalized supplements, and probiotic subscriptions. Its edge lies in combining microbiome data with cellular insights and applying AI-driven, ongoing personalized wellness guidance to help people optimize health.

About Viome Life Sciences

Simplify's Rating
Why Viome Life Sciences is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

AI & Machine Learning

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Series D

Total Funding

$214M

Headquarters

Bellevue, Washington

Founded

2016

Get referred to Viome Life Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 12, 2026 acquisition of Circulate expands Viome’s clinic reach from 40 sites toward 400.
  • April 14, 2025 Full Body Intelligence launch widened Viome’s product suite to $399 recurring testing.
  • July 2025 Microsoft collaboration supports faster processing, deeper analytics, and defensible scale versus smaller competitors.

What critics are saying

  • NAD’s March 2026 ruling forced Viome to soften cancer-detection and comparative accuracy claims.
  • Viome’s tests remain non-FDA-cleared wellness products, inviting regulatory scrutiny if claims outrun evidence.
  • Consumer demand can collapse if scientists dismiss microbiome, RNA, and plasma-exchange benefits as unproven.

What makes Viome Life Sciences unique

  • Viome’s RNA metatranscriptomics analyzes active biology, not just microbiome composition, across stool, saliva, and blood.
  • August 2026 Circulate Health acquisition adds therapeutic plasma exchange, extending Viome from diagnostics into treatment.
  • Microsoft Azure partnership in July 2025 gives Viome scalable infrastructure for its 1-million-sample dataset.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$214M

Below

Industry Average

Funded Over

8 Rounds

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Below Average

Industry standards

$77M
$25M
Viome Life Sciences
$50M
Hello Fresh
$70M
Twilio
$80M
Handshake
$100M
Affirm

Benefits

Health Insurance

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
GeekWire
Aug 12th, 2026
Seattle longevity startups merge: Viome acquires plasma exchange pioneer Circulate Health for $15M–$50M

Seattle-area longevity startups Viome Life Science and Circulate Health are merging. Viome acquired Circulate for between $15 million and $50 million, though specifics were not disclosed. Viome sells at-home test kits for saliva, blood, and stool samples, offering personalised supplements based on results. It has also developed RNA biomarker diagnostics, including an oral and throat cancer test with FDA breakthrough designation. Circulate provides therapeutic plasma exchange services through specially trained nurses, aiming to remove inflammatory factors and aging-associated compounds from blood. The combined company has 115 full-time employees and 10 consultants. Most Circulate staff retained their positions. The merger could expand their reach from 40 clinics to 400 sites. Circulate raised $14 million before acquisition. Viome, founded a decade ago, has raised approximately $250 million. Both microbiome testing and plasma exchange face questions regarding scientific evidence supporting their health benefit claims.

The Healthcare Technology Report
Jul 18th, 2025
Viome Partners with Microsoft to Advance Preventive Healthcare Using RNA and AI

Viome will integrate its extensive dataset of human and microbial gene expression with Microsoft Azure's secure and scalable infrastructure services, including Ultra Disk Storage and Virtual Machines.

WisdomInterface
Apr 14th, 2025
Viome Launches AI-Powered Full Body Intelligence(TM) Test To Help You Stay Healthy, Slow Aging, and Make Illness Optional

BELLEVUE, Wash., April 14, 2025 /PRNewswire/ - Viome Life Sciences, the leader in AI-powered, RNA-driven molecular diagnostics and precision nutrition, today launched its most transformative consumer product, redefining how individuals understand, track, and improve their health through evolving biological insights.

PR Newswire
Apr 14th, 2025
Viome Launches Ai-Powered Full Body Intelligence™ Test To Help You Stay Healthy, Slow Aging, And Make Illness Optional

Viome's Full Body Intelligence Test™ is the only science backed at-home test that decodes your body's biological signals to give you precision health insights. It reveals not just what's happening but why , and turns those insights into personalized daily nutrition advice to help you live healthier and longer., and turns those insights into personalized daily nutrition advice to help you live healthier and longer. Built on unique RNA science and cutting-edge AI, Viome's at-home test redefines health by analyzing 100 million biomarkers to detect early signs of biological dysfunction linked to 25+ chronic health conditions.BELLEVUE, Wash., April 14, 2025 /PRNewswire/ -- Viome Life Sciences, the leader in AI-powered, RNA-driven molecular diagnostics and precision nutrition, today launched its most transformative consumer product, redefining how individuals understand, track, and improve their health through evolving biological insights.Viome Launches AI-Powered Full Body Intelligence™ Test To Help You Stay Healthy, Slow Aging, and Make Illness OptionalAt the core of Viome's new experience is the radical idea that your genes are not your destiny, and your health outcomes are not static or predestined but measurable, modifiable, and within your control. Viome is the only company in the world that uses advanced RNA sequencing to decode your body's active gene expression and applies AI to translate that data into practical, daily health guidance. This includes what to eat, what to avoid, why you should eat certain foods, and how your personal health insights are connected to the most common diseases."Our medical industrial complex is reactive and waits until we experience symptoms or develop a disease instead of helping us stay healthy in the first place," said Naveen Jain, Founder and CEO of Viome. "Symptoms that we feel are the body's last cry for help

Vator
Sep 11th, 2024
Microbiome health science company Viome raises $25M to build out its diagnostics division

To run the new diagnostics division, Viome announced it has hired Kal Raman, most recently senior vice president of Non-Media Business, Marketing and Retail Technology at Amazon; before that he was Chief Digital Officer at Samsung and was formerly Chief Operating Officer at Groupon.

Recently Posted Jobs

Sign up to get curated job recommendations

Viome Life Sciences is Hiring for 2 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →